| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 7－(取代－)－8－(取代)－9－(取代的氨基)－6－去甲基－6－去氧四环素及其制备方法、组合物和用途 | CN93109819.X | 1993-08-13 | CN1048719C | 2000-01-26 | 苏费恩; V·J·李; J·J·赫拉夫卡; R·T·泰斯塔 |
| 本发明提供了具下式结构的化合物，其中X，R及R1均如说明书中所定义。这些化合物作为抗生素是有用的。 | ||||||
| 2 | 新颖的7-(取代)-8-(取代)-9-(取代的氨基)-6-去甲基-6-去氧四环素 | CN93109819.X | 1993-08-13 | CN1090267A | 1994-08-03 | 苏费恩; V·J·李; J·J·赫拉夫卡; R·T·泰斯塔 |
| 本发明提供了具有式1结构的化合物。其中X，R及R1均如说明书中所定义。这些化合物作为抗生素是有用的。 | ||||||
| 3 | 聚合性化合物、聚合性组合物、高分子以及光学各向异性体 | CN201280020259.1 | 2012-04-27 | CN103492363B | 2016-08-24 | 坂本圭; 奥山久美 |
| 本发明涉及下述式(I)表示的聚合性化合物。本发明提供具有低融点、溶解性优异、能够以低成本制造，并且可以获得在宽的波长区域能够均匀偏振转换的光学薄膜的聚合性化合物、聚合性组合物、高分子以及光学各向异性体。式中，Y1～Y6表示单键、?O?、?O?C(=O)?、?C(=O)?O?等，G1、G2表示C1～20的2价脂族基团等，Z1、Z2表示C2～10的烯基等，Ax表示具有选自芳族烃环和芳族杂环的至少一个芳环的C2～30的有机基团等，Aｙ表示氢原子、可以具有取代基的C1～20的烷基、或者具有选自芳族烃环和芳族杂环的至少一个芳环的C2～30的有机基团等，A1表示三价芳族基团等，A2、A3表示二价芳族基团等，Q1表示氢原子、C1～6的烷基等。 | ||||||
| 4 | 环丙基肼盐酸盐的制备方法 | CN201510909317.1 | 2015-12-10 | CN105503647A | 2016-04-20 | 蒋兆芹; 孙豪义; 李宏林 |
| 本发明提供了一种环丙基肼盐酸盐的制备方法，包括以下步骤：（1）环丙胺与N-Boc-O-对甲苯磺酰基羟胺或N-Boc-O-甲磺酰基羟胺或N-Boc-O-2,4,6-三甲苯磺酰基羟胺在有机溶剂中，在N-甲基吗啉作用下在0-20℃反应得到中间体N-Boc-环丙基肼；（2）步骤（1）中得到的中间体N-Boc-环丙基肼与氯化氢的水溶液发生脱保护反应，脱去Boc保护基得到环丙基肼盐酸盐。本发明的方法操作条件温和、简便，可大大降低成本，提高收率，适合于工业化生产，具有良好的应用前景。 | ||||||
| 5 | 聚合性化合物、聚合性组合物、高分子以及光学各向异性体 | CN201280020259.1 | 2012-04-27 | CN103492363A | 2014-01-01 | 坂本圭; 奥山久美 |
| 本发明涉及下述式(I)表示的聚合性化合物。本发明提供具有低融点、溶解性优异、能够以低成本制造，并且可以获得在宽的波长区域能够均匀偏振转换的光学薄膜的聚合性化合物、聚合性组合物、高分子以及光学各向异性体。式中，Y1～Y6表示单键、-O-、-O-C(=O)-、-C(=O)-O-等，G1、G2表示C1～20的2价脂族基团等，Z1、Z2表示C2～10的烯基等，Ax表示具有选自芳族烃环和芳族杂环的至少一个芳环的C2～30的有机基团等，Aｙ表示氢原子、可以具有取代基的C1～20的烷基、或者具有选自芳族烃环和芳族杂环的至少一个芳环的C2～30的有机基团等，A1表示三价芳族基团等，A2、A3表示二价芳族基团等，Q1表示氢原子、C1～6的烷基等。 | ||||||
| 6 | 含铜胺氧化酶的碳环肼基抑制剂 | CN02812891.5 | 2002-07-11 | CN1520290A | 2004-08-11 | D·J·史密斯; F·富洛普; M·皮赫拉维斯托; L·拉萨尔; S·阿拉兰塔; P·瓦伊尼奥; Z·绍科尼 |
| 本发明涉及作为含铜胺氧化酶抑制剂的碳环肼基化合物或药学上可接受的溶剂化物、水合物或它们的盐，已知这些化合物可作为氨基脲敏感性胺氧化酶(SSAO)的抑制剂，包括已知作为血管粘附蛋白－1(VAP－1)的人类SSAO的抑制剂。这些SSAO抑制剂具有治疗某些紊乱和疾病的治疗作用，所述紊乱和疾病包括，但不限于大量的炎性紊乱和疾病(特别是慢性炎性紊乱如慢性关节炎、炎性肠疾病和慢性皮肤病)、与碳水化合物代谢相关的疾病、与脂肪细胞分化或功能异常或平滑肌细胞功能异常相关的疾病以及各种血管疾病。所述新的化合物具有通式(I)，其中R1－R11如文中定义。 | ||||||
| 7 | 含有硝基乙烯胺衍生物或其盐作为有效成分的医药组合物 | CN99811197.X | 1999-09-21 | CN1319007A | 2001-10-24 | 加藤文法; 宫田敬三; 木村博彦; 山元一浩; 池上博之; 猛尾広海 |
| 含有通式(Ⅰ)所示硝基乙烯胺衍生物或其盐作为有效成分的医药组合物，式中,R1为氢、可被取代的烷基、链烯基、炔基、环烷基、环烯基、芳基、杂环基或氰基;R2和R3各自为氢,可被取代的烷基、链烷基、炔基、环烷基、环烯基、芳基或杂环基,或－A－R7基(A为S、SO、SO2、SO3、CO或CO2,R7为氢或可被取代的烷基、链烷基、炔基、环烷基、环烯基、芳基或杂环基);或R2和R3可形成N=CR8R9(式中,R8和R9各自为氢,可被取代的烷基、链烯基、炔基、环烷基、环烯基、芳基或杂环基、烷氧基、芳氧基、氰基、硝基,或－A－R7基);R4和R5各自为氢,可被取代的烷基、链烯基、炔基、环烷基、环烯基、芳基或杂环基、烷氧基、氨基或芳氧基、－A－R7基、氰基、酯基或羟基;或R4和R5可形成N=CR8R9;R6为氢、硝基、氰基、－A－R7基,可被取代的烷基、链烯基、炔基、环烷基、环烯基、芳基或杂环基、烷氧基、氨基或卤原子;R1、R2、R3、R4和R5可形成含杂原子或不含杂原子的环。 | ||||||
| 8 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC BODY | US14114073 | 2012-04-27 | US20140142266A1 | 2014-05-22 | Kei Sakamoto; Kumi Okuyama |
| The present invention relates to a polymerizable compound represented by a formula (I). The present invention provides a polymerizable compound, a polymerizable composition, a polymer, and an optically anisotropic article that are capable of obtaining an optical film having a low melting point, having excellent solubility, capable of being manufactured at low cost, and capable of uniform polarized light conversion across a broad wavelength region. [In formula: Y1 to Y6 are independently a chemical single bond, —O—, —O—C(═O)—, —C(═O)—O— etc.; G1 and G2 are independently a divalent C1-C20 aliphatic group etc.; Z1 and Z2 are independently C2-C10 alkenyl group that is substituted with a halogen atom etc.; Ax is a C2-C30 organic group that includes at least one aromatic ring selected from a group consisting of an aromatic hydrocarbon ring and an aromatic hetero ring; Ay is a hydrogen atom, a C1-C20 alkyl group, a C2-C20 alkenyl group, a C3-C12 cycloalkyl group etc.; A1 is a trivalent aromatic group etc.; A2 and A3 are independently a divalent C6-C30 aromatic group etc.; and Q1 is a hydrogen atom, or a C1-C6 alkyl group etc.] | ||||||
| 9 | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | US10483291 | 2004-06-30 | US20040236108A1 | 2004-11-25 | David John Smith; Ferenc Fulop; Marjo Pihlavisto; Laszlo Lazar; Sakari Alaranta; Petri Vainio; Zsolt Szakonyi |
| The present invention is directed to carbocyclic hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The novel compounds have the general formula: 1 or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein R1 to R11 are as defined herein. | ||||||
| 10 | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | US09902789 | 2001-07-12 | US20030125360A1 | 2003-07-03 | David John Smith; Ferenc Fulop; Marjo Pihlavisto; Laszlo Lazar; Sakari Alaranta; Petri Vainio; Zsolt Szakonyi |
| The present invention is directed to carbocyclic hydrazino compounds that function as inhibitors of copper-containg amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-I (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The novel compounds have the general formula: 1 or a pharmaceutically acceptable solvate, hydrate, or salt thereof wherein R1 to R11 are as defined herein. | ||||||
| 11 | Medical composition containing nitroetheneamine derivative or salt thereof as active constituent | US10133752 | 2002-04-29 | US20020198184A1 | 2002-12-26 | Fuminori Kato; Keizo Miyata; Hirohiko Kimura; Kazuhiro Yamamoto; Hiroyuki Ikegami; Hiromi Takeo |
| The present invention provides a medical composition containing, as an active constituent, a nitroetheneamine derivative represented by the formula (I): 1 wherein R1 is hydrogen, an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group, or cyano; each of R2 and R3 is hydrogen, an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group, or -A-R7 (A is S, SO, SO2, SO3, CO or CO2, and R7 is hydrogen, or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group); or R2 and R3 may form NnullCR8R9 (each of R8 and R9 is hydrogen, an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, alkoxy or aryloxy group, cyano, nitro, or -A-R7 (A and R7 are as defined above); each of R4 and R5 is hydrogen, an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, alkoxy, amino or aryloxy group, -A-R7 (A and R7 are as defined above), cyano, ester, or a hydroxyl group; or R4 and R5 may form NnullCR8R9 (R8 and R9 are as defined above); R6 is hydrogen, nitro, cyano, -A-R7 (A and R7 are as defined above), an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, alkoxy or amino group, or halogen; and further R1, R2, R3, R4 and R5 may form a ring containing or not containing a hetero atom; or a salt thereof. | ||||||
| 12 | 重合性化合物、重合性組成物、高分子、及び光学異方体 | JP2013512458 | 2012-04-27 | JPWO2012147904A1 | 2014-07-28 | 坂本 圭; 圭 坂本; 久美 奥山 |
| 本発明は、下記式(I)で示される重合性化合物に関する。本発明によれば、低い融点を有し、溶解性に優れ、低コストで製造可能で、かつ、広い波長域において一様の偏光変換が可能な光学フィルムを得ることができる、重合性化合物、重合性組成物、高分子、及び光学異方体が提供される。〔式中、Y1〜Y6は単結合、−O−、−O−C(=O)−、−C(=O)−O−等を、G1、G2はC1〜20の2価の脂肪族基等を、Z1、Z2はC2〜10のアルケニル基等を、Axは芳香族炭化水素環及び芳香族複素環からなる群から選ばれる少なくとも一つの芳香環を有する、C2〜30の有機基等を、Ayは水素原子、置換基を有していてもよいC1〜20のアルキル基、又は、芳香族炭化水素環及び芳香族複素環からなる群から選ばれる少なくとも一つの芳香環を有する、C2〜30の有機基等を、A1は三価の芳香族基等を、A2、A3は二価の芳香族基等を、Q1は、水素原子、C1〜6のアルキル基等を表す。〕 | ||||||
| 13 | Thrombopoietin mimetic | JP2004510805 | 2003-06-06 | JP2006501164A | 2006-01-12 | ディルク・アー・ヘールディング |
| 非ペプチドTPO疑似体が発明された。 本発明による化合物の調製に使用される新規方法および中間体も発明された。 また、治療を必要とするヒトを含む哺乳類における血小板減少症の治療方法も発明され、該方法は、かかる哺乳類に有効量の選択されたヒドロキシ-1-アゾベンゼン誘導体を投与することを含む。 | ||||||
| 14 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC MATERIAL | EP18210839.9 | 2012-04-27 | EP3483141A2 | 2019-05-15 | Sakamoto, Kei; Okuyama, Kumi |
The present invention relates to: a hydrazine compound represented by formula (3), wherein Ax and Ay have the meanings indicated in claims 1 to 5; a method for producing an optically anisotropic article by (i) obtaining a polymerizable compound by reacting the hydrazine compound with a carbonyl compound, (ii) forming an alignment film on a substrate, and (iii) forming a liquid crystal layer on the alignment film using the polymer obtained by polymerizing the polymerizable compound or a polymerizable composition including the polymerizable compound and an initiator; and a method for producing a polymerizable compound represented by formula (I), by reacting the hydrazine compound with a carbonyl compound represented by formula (4). The film thus obtained has a low melting point, excellent solubility, is capable of being manufactured at low cost, and capable of uniform polarized light conversion across a broad wavelength region.
|
||||||
| 15 | Novel 7-(substituted)-8-(substituted)-9-(substituted amino)-6-demethyl-6-deoxyetracyclines as antibiotic agents | EP93109850.3 | 1993-06-21 | EP0582810B1 | 2002-04-03 | Sum, Phaik-Eng; Lee, Ving J.; Hlavka, Joseph J.; Testa, Raymond T. |
| 16 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC MATERIAL | US14920294 | 2015-10-22 | US20160145363A1 | 2016-05-26 | Kei SAKAMOTO; Kumi OKUYAMA |
| The present invention relates to a polymerizable compound represented by a formula (I). The present invention provides a polymerizable compound, a polymerizable composition, a polymer, and an optically anisotropic article that are capable of obtaining an optical film having a low melting point, having excellent solubility, capable of being manufactured at low cost, and capable of uniform polarized light conversion across a broad wavelength region. [In formula: Y1 to Y6 are independently a chemical single bond, —O—, —O—C(═O)—, —C(═O)—O— etc.; G1 and G2 are independently a divalent C1-C20 aliphatic group etc.; Z1 and Z2 are independently C2-C10 alkenyl group that is substituted with a halogen atom etc.; Ax is a C2-C30 organic group that includes at least one aromatic ring selected from a group consisting of an aromatic hydrocarbon ring and an aromatic hetero ring; Ay is a hydrogen atom, a C1-C20 alkyl group, a C2-C20 alkenyl group, a C3-C12 cycloalkyl group etc.; A1 is a trivalent aromatic group etc.; A2 and A3 are independently a divalent C6-C30 aromatic group etc.; and Q1 is a hydrogen atom, or a C1-C6 alkyl group etc.] | ||||||
| 17 | Thrombopoietin mimetics | US10516988 | 2003-06-06 | US07414040B2 | 2008-08-19 | Dirk A. Heerding |
| Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative. | ||||||
| 18 | Medical composition containing nitroetheneamine Derivative or salt there of as active constituent | US10133752 | 2002-04-29 | US06596863B2 | 2003-07-22 | Fuminori Kato; Keizo Miyata; Hirohiko Kimura; Kazuhiro Yamamoto; Hiroyuki Ikegami; Hiromi Takeo |
| Process for producing a nitroetheneamine derivative or its stereoisomer, its tautomer or a salt thereof comprising reacting a compound of the formula with a compound of the formula R6—CH2NO2 to obtain a compound of the formula and reacting the resulting compound with a compound of the formula | ||||||
| 19 | 7-(substituted)-8-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines | US454966 | 1995-05-31 | US5512553A | 1996-04-30 | Phaik-Eng Sum; Ving J. Lee; Joseph J. Hlavka; Raymond T. Testa |
| The invention provides compounds of formula ##STR1## wherein X, R and R.sup.1 are defined in the specification. These compounds are useful as antibiotic agents. | ||||||
| 20 | 7-(substituted-9-(substituted amino)-6-demethyl-6-deoxytetracyclines | US352407 | 1994-12-08 | US5495018A | 1996-02-27 | Phaik-Eng Sum; Ving J. Lee; Joseph J. Hlavka; Raymond T. Testa |
| The invention provides compounds of the formulas ##STR1## which are useful as intermediates for the preparation of 6-demethyl-6-deotetracycline antibiotic agents. | ||||||
QQ群二维码
意见反馈
意见反馈